Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced a conference call on August 15, 2022, at 8:30 AM ET to present its Q1 fiscal 2023 financial results and operational highlights. Investors can join the call by dialing 1-877-407-9716 (Canada/US) or 1-201-493-6779 (international) with conference ID 13731985. A live webcast will also be available on their website, along with an archived version post-event. Medicenna focuses on developing innovative immunotherapy treatments, specifically Superkines targeting IL-2, IL-4, and IL-13.
- None.
- None.
TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET to report its first quarter fiscal 2023 financial results and operational highlights.
To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed by the conference ID: 13731985. To access the live webcast, please go visit https://viavid.webcasts.com/starthere.jsp?ei=1560574&tp_key=dc821e35e8. Following the live webcast, an archived version of the call will be available on Medicenna’s website.
About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines.
FAQ
When will Medicenna report its Q1 fiscal 2023 financial results?
How can I access the Medicenna conference call?
Is there a live webcast for Medicenna's financial results?
What is the focus of Medicenna Therapeutics?
